POST-VACCINATION IMMUNE RESPONCE IN SERONEGATIVE TO INFLUENZA VIRUS HIV-INFECTED PATIENTS

The purpose of the study. To evaluate immunogenicity of influenza vaccination in HIV-infected adults initially seronegative to influenza virus.

Materials and methods. There were 175 HIV-infected persons and 50 healthy volunteers vaccinated against influenza in Republican center of AIDS (Ufa) in 2016-November. Titers of antibodies to influenza virus (A [H1N1], A [H3N2] and B) were detected in standard hemagglutination-inhibition reaction: before (day 0) and after (on 21th and 150th days) vaccination. Post-vaccination trends of antibodies to influenza virus were analyzed in 12 HIV-infected patients (7%) and 13 subjects from control group (26%) with the titer of antibodies lower than protective level (1/40) according to the criteria of immunogenicity for influenza vaccines for all subtypes of its antigens.

Results. The shares of initially seronegative were 2–7% for HIV-infected and 12–24% Saint-Petersburg for healthy persons. Seroconversion coefficient varied from 1,6 to 2,3; seroconversion rate varied from 0 to 25%; seroprotection rate – from 67% for А (H1N1) to 100% for А (H3N2) and В. The titer of antibodies detected on day 21 didn’t decrease up to day 150 in all vaccinated persons.

The analysis of the titer in HIV-infected adults with the different levels of CD4-cells demonstrated achievement of minimal protective level (1/40) in the majority of cases, and at least fourfold increase of the titer was determined when CD4-cells level was 350 cells/μl.

Conclusion. Single immunization of HIV-infected adults with standard vaccine for seasonal prevention of influenza is insufficient for creation of adequate immune response. A small sample of the study does not allow extrapolating the results of studies to large cohorts of patients with HIV infection. Further research is required to develop recommendations for vaccine prevention of influenza in patients with HIV infection.

1. Metodicheskie rekomendacii po diagnostike i lecheniju grippa. Ministerstvo zdravoohranenija Rossijskoj Federacii. Moskva, 2016. URL: https://petrsu.ru/files/user/fdbd9903df09bb6f04f397450a13732b/Recom_Flu.pdf

2. Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001;161:441-6.

3. Rekomendacii Evropejskogo regional’nogo bjuro VOZ po vakcinacii protiv grippa v zimnij sezon 2016–2017 гг. URL: http://www.euro.who.int/__data/assets/pdf_ file/0004/321844/recommendations-influenza-vaccination2016-2017-winter-season-ru.pdf

4. Zbinden D, Manuel O. Influenza vaccination in immunocompromised patients: efficacy and safety. Immunotherapy. 2014;6(2):131-9.

5. Remschmidt C, Wichmann O, Harder T. Influenza vaccination in HIV-infected individuals: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness and safety. Vaccine. 2014 Sep 29;32(43):5585-92.

6. Ceravolo A, Orsi A, Parodi V, et al. Influenza vaccination in HIV-positive subjects: latest evidence and future perspective. J prev med hyg. 2013; 54: 1-10.

7. Crum-Cianflone NF, Wallace MR. Vaccination in HIVinfected adults. AIDS Patient Care STDS. 2014 Aug; 28(8):397- 410.

8. Kim DK, Riley LE, Harriman KH, Hunter P, Bridges CB; on behalf of the Advisory Committee on Immunization Practices Recommended immunization schedule for adults aged 19 years or older, United States, 2017. Ann Intern Med. 2017;166:209– 219.

9. British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015. http://www.bhiva.org/ documents/Guidelines/Immunisation/consultation/BHIVAImmunisation-Guidelines-2015-Consultation.pdf. Accessed Mar 30, 2017.

10. European AIDS Clinical Society (EACS) Guidelines for the treatment of HIV. Version 8.2. January 2017. http://www. eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines. html. Accessed Mar 30, 2017.

11. Crum-Cianflone NF, Sullivan E. Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part I. Infect Dis Ther. 2017 Sep; 6(3): 303–331.

12. Frésard A, Gagneux-Brunon A, Lucht F, et al. Immunization of HIV-infected adult patients — French recommendations. Hum Vaccin Immunother. 2016 Nov; 12(11): 2729–2741.

13. The Australian immunization handbook. 10th ed. 2013: 158.

14. Kharit S.M., Ruleva A.A., Goleva O.V., Kalinogorskaya O.S., Apryatina V.A. Results of the Immunization According to the National Calendar Associated with Vaccination against Influenza in Children with Somatic Disorders and Immunodeficiency // Voprosy sovremennoi pediatrii. 2014; 13 (1): 148– 154.

15. Klinicheskie rekomendacii (protokol lechenija) okazanija medicinskoj pomoshhi detjam s klinicheskoj situaciej «Vakcinoprofilaktika detej s VICh-infekciej (В-23)», 2015. URL: http://niidi.ru/dotAsset/7c142c9c-4b64-444d-b1f4-af74af7386d8.pdf

16. Metody opredelenija kachestva immunobiologicheskih preparatov dlja profilaktiki grippa // Metodicheskie ukazanija MU 3.3.2.1758-03. — М., 2003

17. Concept Paper on the Revision of the CPMP/BWP Note for Guidance on Harmonization of Requirements for influenza Vaccines (CPMP/BWP/214/96). London, 31 May, 2001 / CPMP/EWP/1045/01.